The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Teresa Macarulla
Consulting or Advisory Role - AstraZeneca; Baxalta; Baxter; Celgene; Eisai; Genzyme; Incyte; Ipsen; Lilly; Menarini; MSD; Polaris; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire; Surface Oncology
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Milind M. Javle
Consulting or Advisory Role - AstraZeneca; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Sam Joseph Lubner
No Relationships to Disclose
 
Jorge Adeva
No Relationships to Disclose
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Abbvie (Inst); AstraZeneca; BMS (Inst); BMS (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
Daniel V.T. Catenacci
Honoraria - Amgen; Archer; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Natera; Pieris Pharmaceuticals; QED Therapeutics; Seagen; Taiho Pharmaceutical; Tempus; Zymeworks
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech/Roche; Guardant Health; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
John A. Bridgewater
Honoraria - Merck Serono; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER
 
William Proctor Harris
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Neo Therma; QED therapeutics; Zymeworks
Research Funding - Agios (Inst); ArQule (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); BTG (Inst); Exelixis (Inst); Halozyme (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Eisai
 
Adrian Gerard Murphy
Consulting or Advisory Role - Abbvie
Research Funding - Bristol-Myers Squibb
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Lilly; MSD; Novartis; SERVIER
 
Jonathan R. Whisenant
No Relationships to Disclose
 
Christina X. Chamberlain
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Liewen Jiang
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Camelia Gliser
Employment - Agios; KSQ Therapeutics (I)
Stock and Other Ownership Interests - Agios; Agios (I); KSQ Therapeutics (I); KSQ Therapeutics (I); KSQ Therapeutics (I)
 
Shuchi Sumant Pandya
Employment - Agios
Stock and Other Ownership Interests - Agios
Research Funding - Agios
Travel, Accommodations, Expenses - Agios
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; Aptitude Health; AstraZeneca; Baxter; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Wren Laboratories; Zymeworks
Speakers' Bureau - Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana
Travel, Accommodations, Expenses - Lilly; Nucana; Pfizer
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)